Carla Casulo

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment
    Carla Casulo
    Wilmot Cancer Center, University of Rochester, Rochester, NY CC, JWF Columbia University Medical Center, New York, NY OO Seattle Cancer Care Alliance, Seattle, WA AS University of Texas MD Anderson Cancer Center, Houston, TX MF Department of Medicine, Weil Cornell University, New York, NY JPL Oncology Division, Washington University, St Louis, MO BSK Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD RFL University of California Irvine Chao Family Comprehensive Cancer Center in Orange, CA LPB Stanford Cancer Institute, Stanford University, Stanford, CA RA Memorial Sloan Kettering Cancer Center, New York, NY SH
    J Natl Cancer Inst 109:. 2017
  2. doi request reprint Treating Burkitt Lymphoma in Adults
    Carla Casulo
    Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA
    Curr Hematol Malig Rep 10:266-71. 2015
  3. pmc A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
    Carla Casulo
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Electronic address
    Clin Immunol 154:37-46. 2014
  4. doi request reprint Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma
    Carla Casulo
    Department of Medicine, University of Rochester, Rochester, NY, USA
    Leuk Res 37:1178-83. 2013
  5. pmc 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma
    Carla Casulo
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 54:2163-7. 2013
  6. pmc Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?
    Carla Casulo
    Memorial Sloan Kettering Cancer Center, New York, NY 10165, USA
    Curr Oncol Rep 12:374-82. 2010
  7. pmc Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections
    Carla Casulo
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Lymphoma Myeloma Leuk 13:106-11. 2013
  8. doi request reprint Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma
    Patrick M Reagan
    Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY Electronic address
    Clin Lymphoma Myeloma Leuk 16:322-328.e2. 2016
  9. doi request reprint Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse
    Sughosh Dhakal
    Department of Radiation Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York
    Int J Radiat Oncol Biol Phys 96:372-8. 2016

Collaborators

Detail Information

Publications9

  1. doi request reprint T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment
    Carla Casulo
    Wilmot Cancer Center, University of Rochester, Rochester, NY CC, JWF Columbia University Medical Center, New York, NY OO Seattle Cancer Care Alliance, Seattle, WA AS University of Texas MD Anderson Cancer Center, Houston, TX MF Department of Medicine, Weil Cornell University, New York, NY JPL Oncology Division, Washington University, St Louis, MO BSK Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD RFL University of California Irvine Chao Family Comprehensive Cancer Center in Orange, CA LPB Stanford Cancer Institute, Stanford University, Stanford, CA RA Memorial Sloan Kettering Cancer Center, New York, NY SH
    J Natl Cancer Inst 109:. 2017
    ....
  2. doi request reprint Treating Burkitt Lymphoma in Adults
    Carla Casulo
    Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA
    Curr Hematol Malig Rep 10:266-71. 2015
    ..Most Burkitt lymphoma patients are cured with intensive treatment; however, prognosis is poor in elderly patients and those with relapsed disease. ..
  3. pmc A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
    Carla Casulo
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Electronic address
    Clin Immunol 154:37-46. 2014
    ....
  4. doi request reprint Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma
    Carla Casulo
    Department of Medicine, University of Rochester, Rochester, NY, USA
    Leuk Res 37:1178-83. 2013
    ..However, the impact of TAM in relapsed and refractory disease is unknown...
  5. pmc 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma
    Carla Casulo
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 54:2163-7. 2013
    ..Interim FDG-PET may predict for PFS. FDG-PET should be integrated into prospective trials to confirm these findings...
  6. pmc Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?
    Carla Casulo
    Memorial Sloan Kettering Cancer Center, New York, NY 10165, USA
    Curr Oncol Rep 12:374-82. 2010
    ..This article seeks to review the literature on the role of ASCT in PTCL, as well as to clarify what may be the optimal disease state in which to offer patients with PTCL autologous transplantation, if at all...
  7. pmc Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections
    Carla Casulo
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Lymphoma Myeloma Leuk 13:106-11. 2013
    ..After treatment, 39% (69/179) of patients had low levels of immunoglobulin G. Recurrent sinopulmonary infections were seen in 6.6% (14/211). Intravenous immune globulin appeared to reduce the frequency of infection...
  8. doi request reprint Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma
    Patrick M Reagan
    Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY Electronic address
    Clin Lymphoma Myeloma Leuk 16:322-328.e2. 2016
    ..For these reasons, RIT consolidation after chemoimmunotherapy induction has been our standard treatment approach at the University of Rochester for patients with HT who were ineligible for autologous stem cell transplantation...
  9. doi request reprint Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse
    Sughosh Dhakal
    Department of Radiation Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York
    Int J Radiat Oncol Biol Phys 96:372-8. 2016
    ....